Really good information presented this past week. Read the full article: Invitae to Present New Data Supporting Genetic Testing for All Breast Cancer Patients at the 2020 San Antonio Breast Cancer Symposium.
Plus NVTA is the #1 holding in the ARKG portfolio and has a 251% YTD return. The current $56 share price is not scaring people away. I understand taking profits but Invitae is staying in my portfolio.